MRUS 250117 45.00P (MRUS250117P45000) Stock Options, News & Quotes

US OptionsDetailed Quotes

MRUS250117P45000

Watchlist

5.90
+0.30+5.36%

15min DelayClose Jan 17 16:00 ET

5.90High5.90Low

Intraday

5D
Daily

News

Merus N.V. (MRUS): The Biotech Stock With Biggest Upside Potential
Yahoo FinanceJan 17 11:08 ET
What's Going On With Merus Stock Monday?
BenzingaJan 13 16:17 ET
Merus Shares Are Trading Lower. The Company Announced a Research Collaboration and License Agreement With Biohaven to Co-develop Three Novel Bispecific Antibody Drug Conjugates.
BenzingaJan 13 12:52 ET
Express News | Biohaven Ltd - Merus Will Receive an Upfront Payment and License Fee at ADC Candidate Nomination of First Program
ReutersJan 12 20:06 ET
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
GlobeNewswireJan 12 20:04 ET
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
BenzingaJan 10 12:26 ET

Comments

Meltyy

Dec 10, 2024 05:36

🚀 10 Upcoming PDUFAs in December! ❄️

Buckle up! See FDA PDUFA update 👇
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont oral solution
$BeiGene (BGNE.US)$ ⇨ Tisleli...

TrendTrader

May 24, 2024 13:26

Nice recovery. Scaling in

$Merus (MRUS.US)$

frankinglily

Apr 1, 2024 03:50

Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:

$SPDR S&P Biotech ETF (XBI.US)$
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...

Moomoo AI

Jan 9, 2024 05:10

Merus' high P/S ratio is worrisome due to underwhelming revenue forecasts. The company's declining revenue growth and below-industry growth predictions may cause a drop in the P/S ratio, risking shareholders' investments.

There's Reason For Concern Over Merus N.V.'s (NASDAQ:MRUS) Massive 39% Price Jump

Analysts Notebook

Dec 27, 2023 04:18

Columns Biotech Outlook 2024: Analysts Believe the Biotech Sector is Poised for Recovery Next Year

Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF (XBI.US)$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index (.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...